Development of a new prevention maintenance therapy for postmenopausal women.

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

In spring 1998, breast cancer prevention emerged from being a concept to being a reality. The National Surgical Adjuvant Breast and Bowel Project prevention trial showed that tamoxifen reduced breast cancer by 45% in high-risk women between the ages of 35 and 75. Additionally, an evaluation of 10,550 patients randomized to osteoporosis trials of placebo versus raloxifene demonstrated a 50% reduction in the incidence of breast cancer in woman taking raloxifene. For the future, a Study of Tamoxifen Against Raloxifene (STAR) is ongoing in high-risk postmenopausal women. This chapter describes the biological rationale for the current clinical advances.

Original languageEnglish (US)
Pages (from-to)96-109
Number of pages14
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
Volume151
DOIs
StatePublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Development of a new prevention maintenance therapy for postmenopausal women.'. Together they form a unique fingerprint.

Cite this